Download PDF
Thromb Haemost 1989; 61(02): 314-317
DOI: 10.1055/s-0038-1646583
Original Article
Schattauer GmbH Stuttgart

Effect of the Lupus Anticoagulant on Endothelial Fibrinolytic Activity In Vitro

Robert B Francis Jr.
The Division of Hematology, Department of Medicine, Los Angeles County-University of Southern California Medical Center, Los Angeles, California, USA
,
Sara Neely
The Division of Hematology, Department of Medicine, Los Angeles County-University of Southern California Medical Center, Los Angeles, California, USA
› Author Affiliations
Further Information

Publication History

Received 23 June 1988

Accepted after revision 23 December 1988

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We investigated the effect of plasma and serum from 10 subjects with the lupus anticoaguiant and thrombosis and 9 normal subjects on the secretion of tissue-type plasminogen activator (t-PA) and its rapid inhibitor (type 1 plasminogen activator inhibitor, or PAI-1) by cultured human endothelial cells. Confluent monolayers of human umbilical vein endothelial cells were incubated for 48 hours with plasma or serum diluted ten-fold in serum-free endothelial cell growth medium, and the secretion of t-PA and PAI-1 measured by enzyme-linked immunosorbent assay. No consistent differences in mean t-PA and PAI-1 release were found between cells exposed to normal plasma or serum and plasma or serum from subjects with the lupus anticoagulant and thrombosis. No plasma or serum sample produced consistent inhibition of t-PA release or stimulation of PAI-1 release (defined as t-PA levels less than the mean minus two standard deviations for normal subjects, and PAI-I- levels greater than the mean plus two standard deviations for normal subjects, respectively). These findings do not support a role for altered endothelial fibrinolytic activity in the pathogenesis of thrombosis in subjects with the lupus anticoagulant, and are consistent with previous observations that these subjects have normal fibrinolytic activity in vivo.

Keywords

Fibrinolysis - Thrombosis - Lupus anticoagulant - Antiphospholipid antibodies - Endothelium
 

  • References

  • 1 Bowie EJ W, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 3: 416-430
    PubMedGoogle Scholar
  • 2 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159
    CrossrefPubMedGoogle Scholar
  • 3 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
    CrossrefPubMedGoogle Scholar
  • 4 Boey M, Colaco CC, Gharavi AE, Elkon KB, Loizou S, Hughes GR V. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-1023
    CrossrefPubMedGoogle Scholar
  • 5 Fisher M, McGehee W. Cerebral infarct, TIA, and lupus inhibitor. Neurology 1986; 36: 1234-1237
    CrossrefPubMedGoogle Scholar
  • 6 Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR V. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214
    PubMedGoogle Scholar
  • 7 Hamsten A, Norberg R, Bjorkholm M. et al Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113-116
    PubMedGoogle Scholar
  • 8 Morton KE, Gavaghan TP, Krilis SA. et al Coronary artery bypass graft failure - an autoimmune phenomenon. Lancet 1986; 2: 1353-1357
    PubMedGoogle Scholar
  • 9 Carreras LO, Defreyn G, Machin SS, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-266
    PubMedGoogle Scholar
  • 10 Carreras LO, Vermylen JG. “lupus” anticoagulant and thrombosis - possible role of inhibition of prostacyclin formation. Thromb Haemo-stas 1982; 48: 38-40
    PubMedGoogle Scholar
  • 11 Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants. Blood 1983; 62: 299 a (Abstr)
    PubMedGoogle Scholar
  • 12 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-1194 (Letter)
    CrossrefPubMedGoogle Scholar
  • 13 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis Thromb Haemostas 1986; 55: 309-313
    PubMedGoogle Scholar
  • 14 Angles-Cano E, Sultan Y, Clauvel J-P. Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage J Lab Clin Med 1979; 94: 312-323
    PubMedGoogle Scholar
  • 15 Stalder M, Hauert J, Kruithof EK O, Bachmann F. Release of vascular plasminogen activator (v-PA) after venous stasis: elec-trophoretic-zymographic analysis of free and complexed v-PA. Br J Haematol 1985; 61: 169-176
    CrossrefPubMedGoogle Scholar
  • 16 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
    PubMedGoogle Scholar
  • 17 Juhan-Vague I, Valadier J, Alessi MM, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
    PubMedGoogle Scholar
  • 18 Hamsten A, Wiman B, DeFaire U, Blombäck M. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 19 Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
    CrossrefPubMedGoogle Scholar
  • 20 Francis Jr RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-780
    CrossrefPubMedGoogle Scholar
  • 21 Francis Jr RB, McGehee WW, Feinstein DI. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemostas 1988; 59: 412-414
    PubMedGoogle Scholar
  • 22 Exner T, Richard KK, Kronenberg H. A sensitive test demonstrating the lupus anticoagulant and its behavioral patterns. Br J Haematol 1978; 40: 143-150
    CrossrefPubMedGoogle Scholar
  • 23 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 1973; 52: 2745-2756
    CrossrefPubMedGoogle Scholar
  • 24 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52: 2757-2764
    CrossrefPubMedGoogle Scholar
  • 25 Francis Jr RB, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinico-pathologic correlations. J Lab Clin Med 1987; 110: 541-547
    PubMedGoogle Scholar
  • 26 Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550-554
    CrossrefPubMedGoogle Scholar
  • 27 Rapaport SI, Aas K, Owren PA. The lipid inhibitor of brain: mechanisms of its anticoagulant action and its comparison with the soybean inositol phosphatide inhibitor. J Lab Clin Med 1954; 44: 363-373
    PubMedGoogle Scholar
  • 28 Juhan-Vague I, Moerman B, De Cock F, Aillaud MM, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
    CrossrefPubMedGoogle Scholar
  • 29 Van Hinsbergh VW M, Bertina RM, van Wijngaarden A, van Tilburg NN, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
    PubMedGoogle Scholar
  • 30 Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-169
    CrossrefPubMedGoogle Scholar
  • 31 Declerck PJ, Alessi M-C, Verstreken M, Kruithof EK O, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme- linked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 32 Kruithof EK O, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
    PubMedGoogle Scholar
  • 33 Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97-104
    PubMedGoogle Scholar